Comparison on Treatment Effects of Pharmaceutic Agents for Trigger Point Injection.
- Author:
Soo Jeong HAN
1
;
Kyung Hwan LEE
Author Information
1. Department of Rehabilitation Medicine, School of Medicine, Ewha Womans University, Korea. foammy@hanmail.net
- Publication Type:Original Article
- Keywords:
Myofascial pain syndrome;
Trigger point;
Botulinum toxin type A;
Lidocaine;
Ultrasonography
- MeSH:
Botulinum Toxins, Type A;
Glucose;
Humans;
Lidocaine;
Myofascial Pain Syndromes;
Superficial Back Muscles;
Trigger Points*;
Ultrasonography;
Visual Analog Scale
- From:Journal of the Korean Academy of Rehabilitation Medicine
2007;31(6):750-755
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To compare the effect of pharmaceutic agents which were used in trigger point injection and to establish a relationship between ultrasonographic change in injected muscle and post-injection soreness by a double blinded study. METHOD: Twenty-seven patients who were diagnosed as myofascial pain syndrome with their trigger point in upper trapezius muscle were recruited. They were assigned to four groups by age and sex: lidocaine injection (n=8), normal saline injection (n=6), 20%dextrose injection (n=6), and BTX-A injection (n=7). One physiatrist palpated a trigger point at upper trapezius muscle and injected blinded agents with same volume (1 ml). Ultrasonography for injected muscle was done by 2 weeks after injection. Visual analog scale was evaluated up to twenty three weeks. RESULTS: Mean score of visual analog scale was decreased in all groups. Among the four agents, 0.5% lidocaine and BTX-A showed significant decrement in visual analog scale (p<0.05). Ultrasonographic depth of muscle was increased in BTX-A and 20% dextrose injected group at the end of injection (p<0.05). There were no significant different treatment effect in four pharmaceutic agents. CONCLUSION: In all four groups, trigger point injection showed therapeutic effect for myofascial pain syndrome. Among the four agents, 0.5% lidocaine and BTX-A could reduce pain significantly up to twenty three weeks. Mechanical pressure on muscle fiber was thought to be one of the causes of post-injection soreness.
